Skip to content

Study · Animal study (in vivo) · rat · 2021

15 results

Abaloparatide treatment increases bone formation, bone density and bone strength without increasing bone resorption in a rat model of hindlimb unloading.

Teguh DA, Nustad JL, Craven AE, Brooks DJ, Arlt H, Hu D, Baron R, Lanske B, Bouxsein ML

Bone16 Dec 2020Cited by 9 (Europe PMC)

PMID33338664 (opens in a new tab)DOI10.1016/j.bone.2020.115801 (opens in a new tab)PepBankPUB-33338664
Publisher pagePubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In normal weight-bearing and hindlimb-unloaded rats, abaloparatide increased serum osteocalcin versus vehicle.

    In plain wordsIn rats, abaloparatide increased serum osteocalcin versus vehicle under both loading conditions.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSerum osteocalcin
    Study

    ratn: not reported in source

    Normal weight-bearing and hindlimb unloading
    Comparator
    Matched vehicle group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    ABL treatment increased serum osteocalcin in CON and HLU animals while having no effect on the osteoclast marker TRACP-5b.
    2 context sentences
    Summary · context
    We examined skeletal responses to abaloparatide in young adult male rats with normal weight-bearing and with hindlimb unloading via a pelvic harness.
    Summary · context
    Rats were allocated to four groups (10-12 per group): normal weight-bearing plus vehicle treatment (CON-VEH), normal weight-bearing plus ABL treatment (CON-ABL), hindlimb-unloading plus vehicle (HLU-VEH), or hindlimb-unloading plus ABL (HLU-ABL).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats under both loading conditions, abaloparatide did not affect TRACP-5b versus vehicle.

    In plain wordsIn rats, abaloparatide did not affect TRACP-5b versus vehicle under either loading condition.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeSerum TRACP-5b
    Study

    ratn: not reported in source

    Normal weight-bearing and hindlimb unloading
    Comparator
    Matched vehicle group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    ABL treatment increased serum osteocalcin in CON and HLU animals while having no effect on the osteoclast marker TRACP-5b.
    2 context sentences
    Summary · context
    We examined skeletal responses to abaloparatide in young adult male rats with normal weight-bearing and with hindlimb unloading via a pelvic harness.
    Summary · context
    Rats were allocated to four groups (10-12 per group): normal weight-bearing plus vehicle treatment (CON-VEH), normal weight-bearing plus ABL treatment (CON-ABL), hindlimb-unloading plus vehicle (HLU-VEH), or hindlimb-unloading plus ABL (HLU-ABL).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, abaloparatide increased tibial trabecular bone mass versus vehicle by longitudinal pQCT.

    In plain wordsIn rats, abaloparatide increased tibial trabecular bone mass versus vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTibial trabecular bone mass
    Study

    ratn: not reported in source

    Normal weight-bearing and hindlimb unloading
    Comparator
    Matched vehicle group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Longitudinal peripheral quantitative computed tomography (pQCT) indicated that ABL increased trabecular and cortical bone mass in the tibia.
    2 context sentences
    Summary · context
    We examined skeletal responses to abaloparatide in young adult male rats with normal weight-bearing and with hindlimb unloading via a pelvic harness.
    Summary · context
    Rats were allocated to four groups (10-12 per group): normal weight-bearing plus vehicle treatment (CON-VEH), normal weight-bearing plus ABL treatment (CON-ABL), hindlimb-unloading plus vehicle (HLU-VEH), or hindlimb-unloading plus ABL (HLU-ABL).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, abaloparatide increased tibial cortical bone mass versus vehicle by longitudinal pQCT.

    In plain wordsIn rats, abaloparatide increased tibial cortical bone mass versus vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTibial cortical bone mass
    Study

    ratn: not reported in source

    Normal weight-bearing and hindlimb unloading
    Comparator
    Matched vehicle group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Longitudinal peripheral quantitative computed tomography (pQCT) indicated that ABL increased trabecular and cortical bone mass in the tibia.
    2 context sentences
    Summary · context
    We examined skeletal responses to abaloparatide in young adult male rats with normal weight-bearing and with hindlimb unloading via a pelvic harness.
    Summary · context
    Rats were allocated to four groups (10-12 per group): normal weight-bearing plus vehicle treatment (CON-VEH), normal weight-bearing plus ABL treatment (CON-ABL), hindlimb-unloading plus vehicle (HLU-VEH), or hindlimb-unloading plus ABL (HLU-ABL).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats, abaloparatide improved trabecular and cortical bone mass and architecture at the femur, tibia, and vertebrae versus vehicle.

    In plain wordsIn rats, abaloparatide improved bone mass and architecture at the femur, tibia, and vertebrae versus vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBone mass and architecture by μCT
    Study

    ratn: not reported in source

    Normal weight-bearing and hindlimb unloading
    Comparator
    Matched vehicle group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    ABL was also associated with improved trabecular and cortical bone mass and architectural parameters at the femur, tibia, and vertebrae by μCT.
    2 context sentences
    Summary · context
    We examined skeletal responses to abaloparatide in young adult male rats with normal weight-bearing and with hindlimb unloading via a pelvic harness.
    Summary · context
    Rats were allocated to four groups (10-12 per group): normal weight-bearing plus vehicle treatment (CON-VEH), normal weight-bearing plus ABL treatment (CON-ABL), hindlimb-unloading plus vehicle (HLU-VEH), or hindlimb-unloading plus ABL (HLU-ABL).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In hindlimb-unloaded rats, abaloparatide increased tibial trabecular bone formation versus vehicle.

    In plain wordsIn hindlimb-unloaded rats, abaloparatide increased tibial trabecular bone formation versus vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTibial trabecular bone formation
    Study

    ratn: not reported in source

    Normal weight-bearing and hindlimb unloading
    Comparator
    Matched vehicle group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Tibial histomorphometry indicated increased trabecular and endocortical bone formation with HLU-ABL versus HLU-VEH and with CON-ABL versus CON-VEH, and ABL was also associated with lower trabecular and endocortical osteoclast surfaces.
    2 context sentences
    Summary · context
    We examined skeletal responses to abaloparatide in young adult male rats with normal weight-bearing and with hindlimb unloading via a pelvic harness.
    Summary · context
    Rats were allocated to four groups (10-12 per group): normal weight-bearing plus vehicle treatment (CON-VEH), normal weight-bearing plus ABL treatment (CON-ABL), hindlimb-unloading plus vehicle (HLU-VEH), or hindlimb-unloading plus ABL (HLU-ABL).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In hindlimb-unloaded rats, abaloparatide increased tibial endocortical bone formation versus vehicle.

    In plain wordsIn hindlimb-unloaded rats, abaloparatide increased tibial endocortical bone formation versus vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTibial endocortical bone formation
    Study

    ratn: not reported in source

    Normal weight-bearing and hindlimb unloading
    Comparator
    Matched vehicle group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Tibial histomorphometry indicated increased trabecular and endocortical bone formation with HLU-ABL versus HLU-VEH and with CON-ABL versus CON-VEH, and ABL was also associated with lower trabecular and endocortical osteoclast surfaces.
    2 context sentences
    Summary · context
    We examined skeletal responses to abaloparatide in young adult male rats with normal weight-bearing and with hindlimb unloading via a pelvic harness.
    Summary · context
    Rats were allocated to four groups (10-12 per group): normal weight-bearing plus vehicle treatment (CON-VEH), normal weight-bearing plus ABL treatment (CON-ABL), hindlimb-unloading plus vehicle (HLU-VEH), or hindlimb-unloading plus ABL (HLU-ABL).
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In normal weight-bearing rats, abaloparatide increased tibial trabecular bone formation versus vehicle.

    In plain wordsIn normal weight-bearing rats, abaloparatide increased tibial trabecular bone formation versus vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTibial trabecular bone formation
    Study

    ratn: not reported in source

    Normal weight-bearing and hindlimb unloading
    Comparator
    Matched vehicle group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Tibial histomorphometry indicated increased trabecular and endocortical bone formation with HLU-ABL versus HLU-VEH and with CON-ABL versus CON-VEH, and ABL was also associated with lower trabecular and endocortical osteoclast surfaces.
    2 context sentences
    Summary · context
    We examined skeletal responses to abaloparatide in young adult male rats with normal weight-bearing and with hindlimb unloading via a pelvic harness.
    Summary · context
    Rats were allocated to four groups (10-12 per group): normal weight-bearing plus vehicle treatment (CON-VEH), normal weight-bearing plus ABL treatment (CON-ABL), hindlimb-unloading plus vehicle (HLU-VEH), or hindlimb-unloading plus ABL (HLU-ABL).
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In normal weight-bearing rats, abaloparatide increased tibial endocortical bone formation versus vehicle.

    In plain wordsIn normal weight-bearing rats, abaloparatide increased tibial endocortical bone formation versus vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTibial endocortical bone formation
    Study

    ratn: not reported in source

    Normal weight-bearing and hindlimb unloading
    Comparator
    Matched vehicle group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Tibial histomorphometry indicated increased trabecular and endocortical bone formation with HLU-ABL versus HLU-VEH and with CON-ABL versus CON-VEH, and ABL was also associated with lower trabecular and endocortical osteoclast surfaces.
    2 context sentences
    Summary · context
    We examined skeletal responses to abaloparatide in young adult male rats with normal weight-bearing and with hindlimb unloading via a pelvic harness.
    Summary · context
    Rats were allocated to four groups (10-12 per group): normal weight-bearing plus vehicle treatment (CON-VEH), normal weight-bearing plus ABL treatment (CON-ABL), hindlimb-unloading plus vehicle (HLU-VEH), or hindlimb-unloading plus ABL (HLU-ABL).
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In rats, abaloparatide was associated with lower trabecular osteoclast surface versus vehicle.

    In plain wordsIn rats, abaloparatide was associated with lower trabecular osteoclast surface versus vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseTrabecular osteoclast surface
    Study

    ratn: not reported in source

    Normal weight-bearing and hindlimb unloading
    Comparator
    Matched vehicle group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Tibial histomorphometry indicated increased trabecular and endocortical bone formation with HLU-ABL versus HLU-VEH and with CON-ABL versus CON-VEH, and ABL was also associated with lower trabecular and endocortical osteoclast surfaces.
    2 context sentences
    Summary · context
    We examined skeletal responses to abaloparatide in young adult male rats with normal weight-bearing and with hindlimb unloading via a pelvic harness.
    Summary · context
    Rats were allocated to four groups (10-12 per group): normal weight-bearing plus vehicle treatment (CON-VEH), normal weight-bearing plus ABL treatment (CON-ABL), hindlimb-unloading plus vehicle (HLU-VEH), or hindlimb-unloading plus ABL (HLU-ABL).
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In rats, abaloparatide was associated with lower endocortical osteoclast surface versus vehicle.

    In plain wordsIn rats, abaloparatide was associated with lower endocortical osteoclast surface versus vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseEndocortical osteoclast surface
    Study

    ratn: not reported in source

    Normal weight-bearing and hindlimb unloading
    Comparator
    Matched vehicle group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Tibial histomorphometry indicated increased trabecular and endocortical bone formation with HLU-ABL versus HLU-VEH and with CON-ABL versus CON-VEH, and ABL was also associated with lower trabecular and endocortical osteoclast surfaces.
    2 context sentences
    Summary · context
    We examined skeletal responses to abaloparatide in young adult male rats with normal weight-bearing and with hindlimb unloading via a pelvic harness.
    Summary · context
    Rats were allocated to four groups (10-12 per group): normal weight-bearing plus vehicle treatment (CON-VEH), normal weight-bearing plus ABL treatment (CON-ABL), hindlimb-unloading plus vehicle (HLU-VEH), or hindlimb-unloading plus ABL (HLU-ABL).
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In normal weight-bearing rats, abaloparatide increased modeled vertebral ultimate load versus vehicle.

    In plain wordsIn normal weight-bearing rats, abaloparatide increased modeled vertebral ultimate load versus vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseVertebral ultimate load
    Study

    ratn: not reported in source

    Normal weight-bearing and hindlimb unloading
    Comparator
    Matched vehicle group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Vertebral finite element analysis indicated higher ultimate load and stiffness for CON-ABL versus CON-VEH and for HLU-ABL versus HLU-VEH.
    2 context sentences
    Summary · context
    We examined skeletal responses to abaloparatide in young adult male rats with normal weight-bearing and with hindlimb unloading via a pelvic harness.
    Summary · context
    Rats were allocated to four groups (10-12 per group): normal weight-bearing plus vehicle treatment (CON-VEH), normal weight-bearing plus ABL treatment (CON-ABL), hindlimb-unloading plus vehicle (HLU-VEH), or hindlimb-unloading plus ABL (HLU-ABL).
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In normal weight-bearing rats, abaloparatide increased modeled vertebral stiffness versus vehicle.

    In plain wordsIn normal weight-bearing rats, abaloparatide increased modeled vertebral stiffness versus vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseVertebral stiffness
    Study

    ratn: not reported in source

    Normal weight-bearing and hindlimb unloading
    Comparator
    Matched vehicle group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Vertebral finite element analysis indicated higher ultimate load and stiffness for CON-ABL versus CON-VEH and for HLU-ABL versus HLU-VEH.
    2 context sentences
    Summary · context
    We examined skeletal responses to abaloparatide in young adult male rats with normal weight-bearing and with hindlimb unloading via a pelvic harness.
    Summary · context
    Rats were allocated to four groups (10-12 per group): normal weight-bearing plus vehicle treatment (CON-VEH), normal weight-bearing plus ABL treatment (CON-ABL), hindlimb-unloading plus vehicle (HLU-VEH), or hindlimb-unloading plus ABL (HLU-ABL).
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In hindlimb-unloaded rats, abaloparatide increased modeled vertebral ultimate load versus vehicle.

    In plain wordsIn hindlimb-unloaded rats, abaloparatide increased modeled vertebral ultimate load versus vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseVertebral ultimate load
    Study

    ratn: not reported in source

    Normal weight-bearing and hindlimb unloading
    Comparator
    Matched vehicle group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Vertebral finite element analysis indicated higher ultimate load and stiffness for CON-ABL versus CON-VEH and for HLU-ABL versus HLU-VEH.
    2 context sentences
    Summary · context
    We examined skeletal responses to abaloparatide in young adult male rats with normal weight-bearing and with hindlimb unloading via a pelvic harness.
    Summary · context
    Rats were allocated to four groups (10-12 per group): normal weight-bearing plus vehicle treatment (CON-VEH), normal weight-bearing plus ABL treatment (CON-ABL), hindlimb-unloading plus vehicle (HLU-VEH), or hindlimb-unloading plus ABL (HLU-ABL).
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In hindlimb-unloaded rats, abaloparatide increased modeled vertebral stiffness versus vehicle.

    In plain wordsIn hindlimb-unloaded rats, abaloparatide increased modeled vertebral stiffness versus vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseVertebral stiffness
    Study

    ratn: not reported in source

    Normal weight-bearing and hindlimb unloading
    Comparator
    Matched vehicle group
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 μg/kg/day · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Vertebral finite element analysis indicated higher ultimate load and stiffness for CON-ABL versus CON-VEH and for HLU-ABL versus HLU-VEH.
    2 context sentences
    Summary · context
    We examined skeletal responses to abaloparatide in young adult male rats with normal weight-bearing and with hindlimb unloading via a pelvic harness.
    Summary · context
    Rats were allocated to four groups (10-12 per group): normal weight-bearing plus vehicle treatment (CON-VEH), normal weight-bearing plus ABL treatment (CON-ABL), hindlimb-unloading plus vehicle (HLU-VEH), or hindlimb-unloading plus ABL (HLU-ABL).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.